How we helped
Castalia analyzed ways to better incorporate high-cost narrowly-targeted medicines into the overall decision framework of the pharmaceutical subsidy scheme. We also highlighted how restrictions built into the pharmaceutical benefits scheme, instead of producing savings, led to unnecessary fiscal costs. For example, we studied several high-cost medicines which were funded only for in-house hospital use in order to control costs rather than because in-hospital administration was necessary. We showed that people were being hospitalized unnecessarily just to receive the medicine.